吉西他滨联合卡培他滨一线治疗晚期胰腺癌的Meta分析
胰腺肿瘤;化学疗法;吉西他滨;卡培他滨;Meta分析,谢德荣,杨琼,郭双双,江志敏,陈邓林,梁汉霖,通讯作者:,Gemcitabinepluscapecitabineasafront-linetherapyforadvancedpancrea
 |
| 第1页 |
参见附件(520KB，4页)。
谢德荣, 杨琼, 郭双双, 江志敏, 陈邓林, 中山大学附属第二医院肿瘤科 广东省广州市 510120
梁汉霖, 中山大学附属中山市人民医院化疗科 广东省中山市 528403
通讯作者: 谢德荣, 510120 中山大学附属第二医院肿瘤科. derongxie@126.com
电话: 020-81332616 传真: 020-84110956
收稿日期: 2007-03-16 接受日期: 2007-03-31
Gemcitabine plus capecitabine as a front-line therapy for advanced pancreatic cancer: a meta-analysisDe-Rong Xie, Han-Lin Liang, Qiong Yang Shuang-Shuang Guo, Zhi-Min Jiang, Deng-Lin Chen
De-Rong Xie, Qiong Yang Shuang-Shuang Guo, Zhi-Min Jiang, Deng-Lin Chen, Department of Oncology, The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China
Han-Lin Liang, Department of Chemotherapy, Zhongshan People’s Hospital of Sun Yat-Sen University, Zhongshan 528403, Guangdong Province, China
Correspondence to: De-Rong Xie, Department of Oncology, The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China. derongxie@126.com
Received: 2007-03-16 Accepted: 2007-03-31
Abstract
AIM: To use a meta-analysis to explore the therapeutic effects of gemcitabine (GEM) plus capecitabine (CAP) as a front-line therapy in patients with advanced pancreatic cancer (APCa).
METHODS: A meta-analysis of all previously published and some unpublished studies were performed with a comprehensive search of the literatures included in MEDLINE, EMBASE, ASCO and ECCO. The meta-analysis included all randomized evidence to compare GEM plus CAP (GEMCAP) with GEM alone with respect to overall survival rate, objective remission rate and toxicities in APCa patients.
RESULTS: Of 316 reports, three randomized controlled trials involving 932 APCa patients were identified by two reviewers. The GEMCAP combination group showed a significant improvement in 6-month survival rate (RD = 0.07, 95%CI 0.01-0.13, P = 0.03) and objective remission rate (RD = 0.06, 95%CI 0 ......
您现在查看是摘要介绍页，详见PDF附件(520KB，4页)。